---
schema_version: "secwatch.filing_event.v1"
accession: "0001708599-26-000010"
form_type: "8-K"
ticker: "SER"
cik: "0001708599"
company_name: "Serina Therapeutics, Inc."
filed_at: "2026-03-23T23:59:59+00:00"
generated_at: "2026-05-15T09:22:40.652739+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Serina raises $15M first tranche (up to $30M) at $2.25/share (68% premium); Greg Bailey appointed Co-Chairman

## Summary
- First tranche of $15M closed March 20, 2026; second tranche up to $15M due by April 30, 2026.
- Pricing at $2.25 per share (68% premium to March 17 close); 50% warrant coverage at $5 exercise (273% premium).
- Warrants if fully exercised could add up to $33.3M; total potential funds ~$63.3M to extend runway into 2H 2027.
- Proceeds to fund SER-252 registrational trial for advanced Parkinson's; first patient dosed in SAD study.
- Greg Bailey, M.D., lead investor, appointed Co-Chairman of Board; existing convertible note amended to eliminate further borrowing.

## SEC filing metadata
- accession: 0001708599-26-000010
- form_type: 8-K
- ticker: SER
- cik: 0001708599
- company_name: Serina Therapeutics, Inc.
- filed_at: 2026-03-23T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 1.01, 3.02, 5.02, 5.03, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1708599/000170859926000010/0001708599-26-000010-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1708599/000170859926000010/ser-20260317.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001708599-26-000010
- JSON: https://secwatch.observer/filing/0001708599-26-000010.json
- Plain text: https://secwatch.observer/filing/0001708599-26-000010.txt

## Key facts
- Governance Changes
  Serina Therapeutics, Inc.: Company agreed to amend bylaws to provide for co-chairmen of the Board, with each co-chairman having same rights and responsibilities, effective upon closing of initial tranche of private placement.
  - Change: bylaw amendment
  source text: the Company has agreed to take all necessary actions to effect such appointment and to amend its bylaws to provide for co-chairmen of the Board, with each co-chairman having the same rights and responsibilities.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1708599/000170859926000010/0001708599-26-000010-index.htm
- Material Agreements
  Serina Therapeutics, Inc. amended a notes offering with holders of its outstanding Senior Unsecured Convertible Promissory Note.
  - Action: amendment
  - Agreement: notes offering
  - Counterparty: holders of its outstanding Senior Unsecured Convertible Promissory Note
  source text: As a condition to the initial closing, the Company and the holders of its outstanding Senior Unsecured Convertible Promissory Note, dated September 9, 2025, entered into an amendment of such note, effective upon the initial closing, removing any further obligations to borrow or loan funds under the Note.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1708599/000170859926000010/0001708599-26-000010-index.htm
- Material Agreements
  Serina Therapeutics, Inc. entered into Securities Purchase Agreement with Greg Bailey, as lead investor, and certain other investors valued at $15.0 million (effective 2026-03-17).
  - Action: entry
  - Agreement: equity purchase
  - Counterparty: Greg Bailey, as lead investor, and certain other investors
  - Value: $15.0 million
  - Effective: 2026-03-17
  source text: On March 17, 2026, Serina Therapeutics, Inc. (the “ Company ”) entered into a Securities Purchase Agreement (the “ Purchase Agreement ”) with Greg Bailey, as lead investor, and certain other investors (collectively, the “ Investors ”), pursuant to which the Company agreed to issue and sell, in a private placement (the “ Private Placement ”), shares of its common stock, par value $0.0001 per share (the “ Common Stock ”), pre-funded warrants to purchase shares of Common Stock (the “ Pre-Funded Warrants ”) redeemable warrants to purchase shares of Common Stock (the “ Redeemable Warrants ” and, together with the Common Stock and the Pre-Funded Warrants, the “ Securities ”).
  evidence_url: https://www.sec.gov/Archives/edgar/data/1708599/000170859926000010/0001708599-26-000010-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.